Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intismeran autogene - Merck/Moderna Therapeutics

Next Previous
Drug Profile

Intismeran autogene - Merck/Moderna Therapeutics

Alternative Names: mRNA-4157; mRNA-4157/V940; PCV; Personalised cancer vaccine - Moderna Therapeutics; V-940

Latest Information Update: 21 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics
  • Developer Merck Sharp & Dohme; Moderna Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Malignant melanoma; Non-small cell lung cancer
  • Phase II/III Squamous cell cancer
  • Phase II Bladder cancer; Renal cell carcinoma
  • No development reported Solid tumours

Most Recent Events

  • 19 Aug 2026 Efficacy data from a phase III INTerpath-001 trial in Malignant melanoma released by Moderna Therapeutics
  • 28 Jun 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Australia (IM, Injection)
  • 28 Jun 2026 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in USA (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top